The New Antibodies Revolutionizing Medicine

Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.

While most biotechs struggle amid a prolonged funding winter, one group is doing just fine. We are not talking about artificial intelligence. Several start-ups working on nucleic acid-based therapies – a sprawling category that includes several flavors of RNA, anti-sense oligonucleotides (ASOs), aptamers (short single stranded oligonucleotides) and gene-edited cell and gene therapies – are raising bigger-than-average rounds. Four of the top five private financings in 2023 have been companies working on RNA, gene editing or manufacturing. ReNAgade Therapeutics and Orbital Therapeutics each pulled in over $250m; this year’s biggest round yet brought ElevateBio, with its suite of gene- and cell-editing tools, more than $400m.

These groups are competing for dominance in a field of medicine whose scope, impact and value is being compared to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.